Develops innovative T cell therapies for cancer using a proprietary platform to enhance immune targeting of liquid and solid tumors.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Triumvira Immunologics develops innovative T cell therapies for cancer using its proprietary T Cell Antigen Coupler (TAC) platform, which enhances the immune system’s ability to target and destroy tumor cells. The company’s technology is designed for broad applicability across a wide range of liquid and solid tumors, leveraging advanced manufacturing for both autologous and allogeneic therapeutic candidates.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Triumvira Immunologics Management Team
Investors
Bloom Burton & Co
Centre for Commercialization of Cancer Immunotherapy
Northpond Ventures
Oceanpine Capital
Viva Biotech Holdings
Triumvira Immunologics Valuations & Financials
View real-time NPM data on Triumvira Immunologics stock including daily Triumvira Immunologics stock price estimates, valuation history, and historical share price information. Access Triumvira Immunologics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Triumvira Immunologics pricing across six independent market signals. Looking for private company due diligence data sources on Triumvira Immunologics? Get in touch to learn more.
Similar Companies
like Triumvira Immunologics
Podium
Enterprise Software
Customer messaging platform enabling companies to connect at critical touch points.
Reality Defender
Cybersecurity
Offers a platform that detects AI-generated media across multiple formats, enabling organizations to secure communications and prevent fraudulent activities.
RevBoss
Delivers services that generate leads and build sales pipelines through targeted outreach, content, and automated engagement tools.
Bite
Commerce & Marketplaces
Provides AI-driven self-ordering kiosks that personalize the dining experience, boosting sales and operational efficiency.
Black Sesame Technologies
Develops high-performance semiconductor solutions for intelligent vehicles, integrating imaging, perception, and computing capabilities.
Siren Biotechnology
Healthcare & Life Sciences
Activating how solid tumors are targeted by harnessing vectorized cytokines that ignite immune attack with precision and inherent safety.
Mitsufuji
Develops biometric monitoring solutions and conductive fiber technology to enhance healthcare and workplace safety through wearable IoT devices.
Zuub
Healthcare & Life Sciences
Empowers dental practices with AI automation that simplifies insurance checks and streamlines treatment planning for clearer workflows.
SalonHQ
Manages bookings, client details, and operations to help service professionals run their schedules smoothly.
FAQ
We have answers
Triumvira Immunologics stock does not trade on public stock exchanges. Triumvira Immunologics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Triumvira Immunologics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Triumvira Immunologics Stock does not trade on public stock exchanges. In order to sell Triumvira Immunologics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Triumvira Immunologics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Triumvira Immunologics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Triumvira Immunologics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Triumvira Immunologics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Triumvira Immunologics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Triumvira Immunologics is a private company and has not had an IPO. There is currently no Triumvira Immunologics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Triumvira Immunologics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
